Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update.

Front Gastroenterol (Lausanne) · 2022 · PMC12952304 · PMID 41822072

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Abrilumab, an anti-α4β7 antibody, induced clinical remission in UC, but did not reach statistical significance in CD in phase II trials ( 62 , 63 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.